Gilead Sciences GILD Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $29.74B+1.0% | $29.44B+1.2% | $29.09B+0.8% | $28.86B+0.4% | $28.74B-0.1% | ||
| $6.14B-1.5% | $6.23B+0.7% | $6.19B-0.1% | $6.2B-0.7% | $6.24B-0.2% | ||
| $23.6B+1.7% | $23.21B+1.4% | $22.9B+1.0% | $22.67B+0.8% | $22.5B0.0% | ||
| 79.4%+0.5pp | 78.8%+0.1pp | 78.7%+0.2pp | 78.5%+0.2pp | 78.3%0.0pp | ||
| $5.97B+3.3% | $5.77B-1.9% | $5.89B-1.3% | $5.96B-0.2% | $5.98B-1.9% | ||
| $19.37B-0.3% | $19.42B+4.4% | $18.6B-10.6% | $20.81B+1.5% | $20.51B-24.3% | ||
| $10.37B+3.5% | $10.02B-4.5% | $10.49B+30.3% | $8.05B-2.1% | $8.22B+395% | ||
| 34.9%+0.8pp | 34%-2.0pp | 36.1%+8.2pp | 27.9%-0.7pp | 28.6%+22.8pp | ||
| $1.01B-2.0% | $1.03B+0.6% | $1.02B+1.8% | $1B+1.7% | $984M+0.6% | ||
| $1.36B+70.6% | $798M— | —— | —— | —— | ||
| $10.73B+9.5% | $9.8B-0.9% | $9.89B+37.3% | $7.2B+5.5% | $6.83B+889% | ||
| $1.62B+16.2% | $1.39B-21.7% | $1.78B+99.6% | $890M+3.5% | $860M+308% | ||
| $9.22B+8.3% | $8.51B+4.9% | $8.11B+28.5% | $6.31B+5.8% | $5.97B+1,143% | ||
| 31%+2.1pp | 28.9%+1.0pp | 27.9%+6.0pp | 21.9%+1.1pp | 20.8%+19.1pp | ||
| $7.34+8.4% | $6.77+5.0% | $6.45+28.5% | $5.02+5.7% | $4.75+1,184% | ||
| $10.74B+3.3% | $10.39B-4.4% | $10.87B+28.9% | $8.43B-2.0% | $8.61B+321% | ||
| 36.1%+0.8pp | 35.3%-2.1pp | 37.4%+8.1pp | 29.2%-0.7pp | 29.9%+22.8pp | ||
| $10.37B+3.5% | $10.02B-4.5% | $10.49B+30.3% | $8.05B-2.1% | $8.22B+395% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Gilead Sciences's revenue?
- Gilead Sciences (GILD) generated $29.7B in revenue over the trailing twelve months, up 3.5% year over year.
- Is Gilead Sciences profitable?
- Gilead Sciences reported $9.2B in net income over the trailing twelve months, a 31.0% net margin.
- What are Gilead Sciences's profit margins?
- Gross margin is 79.4% and operating margin is 34.9%, with a 31.0% net margin.
- What is Gilead Sciences's earnings per share?
- Gilead Sciences's diluted EPS over the trailing twelve months is $7.34.
- Where does Gilead Sciences's income statement data come from?
- Every line is extracted from Gilead Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
